Lupin announced the launch of Mycophenolate Mofetil Capsules USP, 250 mg. Lupin's alliance partner Concord Biotech (Concord) had received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.
Mycophenolate Mofetil Capsules USP, 250 mg, is the generic version of Roche's CeiiCept. Mycophenolate Mofetil Capsules are an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, and should be used in combination with other immunosuppressants.
Mycophenolate Mofetil Capsules USP, 250 mg, had annual sales of approximately USD 53 million in the U.S. (IQVIA MAT August 2019).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
